GlassScriptPhysician profile
Sara Niknam
NPI 1790292712
$5,583.99
in general payments reported to CMS, 2019-2025
28 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,563 · 2022: $1,859 · 2023: $562 · 2024: $467 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,897 · Travel and Lodging: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.08 |
| Travel and Lodging | $265.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,221.46 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $499.63 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $493.80 | 2021-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $413.76 | 2021-2025 | Xtampza |
| Curonix LLC | $366.45 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Scilex Pharmaceuticals INC. | $319.03 | 2021-2025 | |
| Abbott Laboratories | $291.46 | 2022-2025 | Eterna, Proclaim |
| Biohaven Pharmaceutical Holding Company LTD. | $286.37 | 2022 | |
| Pfizer INC. | $211.45 | 2021-2025 | |
| Si-Bone, INC. | $165.49 | 2022-2025 | |
| Medtronic, INC. | $149.80 | 2022-2023 | Synchromedii, Intellis Adaptivestim |
| Biodelivery Sciences International, INC. | $141.74 | 2021 | |
| Boston Scientific Corporation | $141.14 | 2021-2023 | |
| Janssen Biotech, INC. | $123.01 | 2023 | Simponi Aria |
| Electronic Waveform Lab, INC. | $117.62 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $99.99 | 2023-2025 | Xeomin |
| Grt US Holding, INC. | $97.74 | 2021 | |
| Merck Sharp & Dohme LLC | $83.76 | 2021-2022 | |
| Forte Bio-Pharma LLC | $75.75 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $70.46 | 2024-2025 | |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Allergan, INC. | $37.03 | 2021 | |
| Nevro Corp. | $27.09 | 2023 | Senza |
| Ibsa Pharma INC. | $25.96 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $22.86 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $19.66 | 2022 | |
| Hologic Sales and Service, LLC | $18.90 | 2021 | |
| Eisai INC. | $17.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Niknam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.